Compare Snowflake Inc (SNOW) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snowflake Inc vs BIO-TECHNE Corp — how do they compare? Snowflake Inc trades at $335.78 (market cap $116.01B), while BIO-TECHNE Corp trades at $72.18 (market cap $11.24B). The key difference: Snowflake Inc is far larger — about 10.3× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Snowflake Inc pays none. Which is the better fit depends on your goals.
| SNOW | TECH | |
|---|---|---|
Market Cap | $116.01B | $11.24B |
Sector | Technology | Health |
52-Week High | $334.70 | $72.29 |
52-Week Low | $121.11 | $43.31 |
Enterprise Value | $115.82B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Snowflake (SNOW) trades at $330.49, up 3.93% in 24 hours, approaching its 52-week high. The stock exhibits bullish technical signals with strong moving average support, though RSI levels indicate overbought conditions. Fundamentally, revenue growth is robust at $3.63 billion in 2025, but net losses persist at -$1.29 billion. Recent news highlights AI-driven partnerships and product launches, such as Spotfire's integration with Snowflake AI Data Cloud (Business Wire, 2026-08-05).
The outlook remains optimistic due to strong analyst buy ratings (80.77%) and a consensus price target of $302.18, though high valuation multiples (P/S 22.37) and ongoing losses pose risks. Key opportunities include AI expansion and customer growth, while competition and margin pressure are concerns. Investors should weigh growth potential against profitability challenges.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
